Woodline Partners »

Humacyte shares owned by Woodline Partners

Quarter-by-quarter ownership of Humacyte (HUMA) shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Humacyte

Tip: Access up to 7 years of quarterly data

All positions including Humacyte held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Humacyte by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $4.6M 849k 5.44

More positions owned by Woodline Partners

Meta Platforms Cl A (META)
Gilead Sciences (GILD)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Vaxcyte (PCVX)
Asml Holding N V N Y Registry Shs (ASML)
Nuvalent Inc-a (NUVL)
Permian Resources Corp Class A Com (PR)
Encana Corporation (OVV)
Keysight Technologies (KEYS)
Danaher Corporation (DHR)
Aon Shs Cl A (AON)
Stmicroelectronics N V Ny Registry (STM)
Regeneron Pharmaceuticals (REGN)
EQT Corporation (EQT)

View all positions for Woodline Partners

Top funds holding Humacyte

BlackRock
BlackRock
Vanguard Group
State Street Corporation
Geode Capital Management
Voloridge Investment Management
Nuveen Asset Management
Two Sigma Investments
Susquehanna International
Woodline Partners
Northern Trust
Goldman Sachs Group
Charles Schwab Investment Management
Marshall Wace
Monashee Investment Management

View all funds holding Humacyte